@article{7de4668baace48cd9e8044ca16f09e28,
title = "A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF",
abstract = "Background & Aims Crohn's disease (CD) has the highest prevalence in Ashkenazi Jewish populations. We sought to identify rare, CD-associated frameshift variants of high functional and statistical effects. Methods We performed exome sequencing and array-based genotype analyses of 1477 Ashkenazi Jewish individuals with CD and 2614 Ashkenazi Jewish individuals without CD (controls). To validate our findings, we performed genotype analyses of an additional 1515 CD cases and 7052 controls for frameshift mutations in the colony-stimulating factor 2–receptor β common subunit gene (CSF2RB). Intestinal tissues and blood samples were collected from patients with CD; lamina propria leukocytes were isolated and expression of CSF2RB and granulocyte-macrophage colony–stimulating factor–responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cytometry (CyTOF analysis). Variants of CSF2RB were transfected into HEK293 cells and the expression and functions of gene products were compared. Results In the discovery cohort, we associated CD with a frameshift mutation in CSF2RB (P = 8.52 × 10-4); the finding was validated in the replication cohort (combined P = 3.42 × 10-6). Incubation of intestinal lamina propria leukocytes with granulocyte-macrophage colony–stimulating factor resulted in high levels of phosphorylation of signal transducer and activator of transcription (STAT5) and lesser increases in phosphorylation of extracellular signal–regulated kinase and AK straining transforming (AKT). Cells co-transfected with full-length and mutant forms of CSF2RB had reduced pSTAT5 after stimulation with granulocyte-macrophage colony–stimulating factor, compared with cells transfected with control CSF2RB, indicating a dominant-negative effect of the mutant gene. Monocytes from patients with CD who were heterozygous for the frameshift mutation (6% of CD cases analyzed) had reduced responses to granulocyte-macrophage colony–stimulating factor and markedly decreased activity of aldehyde dehydrogenase; activity of this enzyme has been associated with immune tolerance. Conclusions In a genetic analysis of Ashkenazi Jewish individuals, we associated CD with a frameshift mutation in CSF2RB. Intestinal monocytes from carriers of this mutation had reduced responses to granulocyte-macrophage colony–stimulating factor, providing an additional mechanism for alterations to the innate immune response in individuals with CD.",
keywords = "Ethnic Variation, IBD, Inflammatory Bowel Disease, Risk Factor",
author = "Chuang, {Ling Shiang} and Nicole Villaverde and Hui, {Ken Y.} and Arthur Mortha and Adeeb Rahman and Levine, {Adam P.} and Talin Haritunians and {Evelyn Ng}, {Sok Meng} and Wei Zhang and Hsu, {Nai Yun} and Facey, {Jody Ann} and Tramy Luong and Heriberto Fernandez-Hernandez and Dalin Li and Manuel Rivas and Schiff, {Elena R.} and Alexander Gusev and Schumm, {L. Phillip} and Bowen, {Beatrice M.} and Yashoda Sharma and Kaida Ning and Romain Remark and Sacha Gnjatic and Peter Legnani and James George and Sands, {Bruce E.} and Stempak, {Joanne M.} and Datta, {Lisa W.} and Seth Lipka and Seymour Katz and Cheifetz, {Adam S.} and Nir Barzilai and Nikolas Pontikos and Clara Abraham and Dubinsky, {Marla J.} and Stephan Targan and Kent Taylor and Rotter, {Jerome I.} and Scherl, {Ellen J.} and Desnick, {Robert J.} and Abreu, {Maria T.} and Hongyu Zhao and Gil Atzmon and Itsik Pe'er and Subra Kugathasan and Hakon Hakonarson and McCauley, {Jacob L.} and Todd Lencz and Ariel Darvasi and Vincent Plagnol and Silverberg, {Mark S.} and Muise, {Aleixo M.} and Brant, {Steven R.} and Daly, {Mark J.} and Segal, {Anthony W.} and Duerr, {Richard H.} and Miriam Merad and McGovern, {Dermot P.B.} and Inga Peter and Cho, {Judy H.}",
note = "Funding Information: Funding Supported by the National Institutes of Health ( DK092235 ), Inflammatory Bowel Disease Genetics Consortium ( DK062429 ), Genetic Research Center at the Icahn School of Medicine ( DK062422 ), New York Crohn{\textquoteright}s Foundation, Consortium ancillary RO1 (DK099097) and U01 (DK062431) , Inflammatory Bowel Disease Genetic Research Chair , RO1 (DK062420) and RO1 (CA141743) , the Atran Foundation, and the Sanford J. Grossman Charitable Trust. Researchers at University College of London were funded by the Wellcome Trust, Charles Wolfson Charitable Trust, and the Irwin Joffe Memorial Fellowship. Inflammatory bowel disease Research at Cedars-Sinai is supported by U.S. Public Health Service grant PO1 (DK046763) and the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute Research Funds. Project investigators are supported by The Helmsley Charitable Trust (D.P.B.M.), The European Union (D.P.B.M.), The Crohn's and Colitis Foundation of America (D.P.B.M.), The Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics (D.P.B.M.), and grants DK062413, DK046763-19, AI067068, and HS021747 (D.P.B.M.). Publisher Copyright: {\textcopyright} 2016 AGA Institute",
year = "2016",
month = oct,
day = "1",
doi = "10.1053/j.gastro.2016.06.045",
language = "English",
volume = "151",
pages = "710--723.e2",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",
}